Connor, Clark & Lunn Investment Management (CC&L)
CASC

Connor, Clark & Lunn Investment Management (CC&L)’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-72,973
Closed -$270K – 867
2017
Q4 		$270K Sell
72,973
-2,000
-3% -$8.19K ﹤0.01% 695
2017
Q3 		$307K Buy
74,973
+4,461
+6% +$17.1K ﹤0.01% 706
2017
Q2 		$262K Buy
70,512
+33,627
+91% +$133K ﹤0.01% 698
2017
Q1 		$153K Buy
+36,885
New +$155K ﹤0.01% 823
2016
Q4 		– Sell
-15,833
Closed -$156K – 1053
2016
Q3 		$156K Hold
15,833
– – ﹤0.01% 751
2016
Q2 		$89K Hold
15,833
– – ﹤0.01% 810
2016
Q1 		$121K Hold
15,833
– – ﹤0.01% 755
2015
Q4 		$211K Hold
15,833
– – ﹤0.01% 694
2015
Q3 		$260K Buy
15,833
+3,016
+24% +$61.8K ﹤0.01% 613
2015
Q2 		$288K Buy
12,817
+434
+4% +$6.87K ﹤0.01% 504
2015
Q1 		$121K Buy
12,383
+2,833
+30% +$27.8K ﹤0.01% 525
2014
Q4 		$109K Buy
9,550
+5,017
+111% +$54.5K ﹤0.01% 548
2014
Q3 		$52K Buy
+4,533
New +$69.2K ﹤0.01% 534

Connor, Clark & Lunn Investment Management (CC&L)'s CASC Position: Q1 2018 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 72,973 shares — an estimated $270K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CASC in Q3 2014 and held it in 13 quarters. The position peaked at $307K in Q3 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 72,973 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $270K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 13 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Cascadian Therapeutics, Inc. position peaked at $307K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2018, filed 14 May 2018.